JP2009537507A - アテローム性動脈硬化症に対して保護的な自己抗体を誘導するＩＬ−１α免疫法 - Google Patents

アテローム性動脈硬化症に対して保護的な自己抗体を誘導するＩＬ−１α免疫法 Download PDF

Info

Publication number
JP2009537507A
JP2009537507A JP2009510567A JP2009510567A JP2009537507A JP 2009537507 A JP2009537507 A JP 2009537507A JP 2009510567 A JP2009510567 A JP 2009510567A JP 2009510567 A JP2009510567 A JP 2009510567A JP 2009537507 A JP2009537507 A JP 2009537507A
Authority
JP
Japan
Prior art keywords
atherosclerosis
mammal
disease
mice
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009510567A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009537507A5 (enExample
Inventor
ジョン シマード
Original Assignee
エクスバイオテク インコーポレーティッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エクスバイオテク インコーポレーティッド filed Critical エクスバイオテク インコーポレーティッド
Publication of JP2009537507A publication Critical patent/JP2009537507A/ja
Publication of JP2009537507A5 publication Critical patent/JP2009537507A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compositions Of Oxide Ceramics (AREA)
JP2009510567A 2006-05-15 2007-05-15 アテローム性動脈硬化症に対して保護的な自己抗体を誘導するＩＬ−１α免疫法 Pending JP2009537507A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80002906P 2006-05-15 2006-05-15
PCT/IB2007/001264 WO2007132338A2 (en) 2006-05-15 2007-05-15 IL-1α IMMUNIZATION INDUCES AUTOANTIBODIES PROTECTIVE AGAINST ATHEROSCLEROSIS

Publications (2)

Publication Number Publication Date
JP2009537507A true JP2009537507A (ja) 2009-10-29
JP2009537507A5 JP2009537507A5 (enExample) 2010-07-01

Family

ID=38694276

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009510567A Pending JP2009537507A (ja) 2006-05-15 2007-05-15 アテローム性動脈硬化症に対して保護的な自己抗体を誘導するＩＬ−１α免疫法

Country Status (9)

Country Link
US (1) US20090191149A1 (enExample)
EP (1) EP2021033B1 (enExample)
JP (1) JP2009537507A (enExample)
CN (1) CN101448528A (enExample)
AT (1) ATE551365T1 (enExample)
AU (1) AU2007251239B2 (enExample)
CA (1) CA2652274A1 (enExample)
ES (1) ES2384278T3 (enExample)
WO (1) WO2007132338A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015019617A (ja) * 2013-07-19 2015-02-02 国立大学法人三重大学 閉塞性動脈硬化症モデル動物、るい痩研究用モデル動物、及び全身性アミロイドーシスモデル動物としての非ヒト哺乳動物

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1915620T3 (da) 2005-08-02 2010-10-04 Xbiotech Inc Diagnose, behandling og prævention af vaskulære sygdomme ved hjælp af IL-1alpha-autoantistoffer
US20110008282A1 (en) * 2006-05-15 2011-01-13 Xbiotech, Inc. IL-1alpha immunization induces autoantibodies protective against atherosclerosis
CN102580086A (zh) * 2006-05-22 2012-07-18 埃克斯生物科技公司 使用抗IL-1α抗体治疗癌症
HUE029003T2 (en) 2008-05-30 2017-01-30 Xbiotech Inc IL-1 alpha antibodies
JP5976319B2 (ja) * 2008-09-12 2016-08-23 エックスバイオテク, インコーポレイテッドXbiotech, Inc. 病原性単球の標的化
EP2569640A1 (en) 2010-05-12 2013-03-20 The University of Birmingham Biomarker
CN102946904A (zh) 2010-06-18 2013-02-27 埃克斯生物科技公司 关节炎治疗
PH12013500316A1 (en) 2010-08-23 2016-09-02 Janssen Biotech Inc Treatment for neoplastic diseases
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
PT2750709T (pt) 2011-09-23 2018-11-22 Xbiotech Inc Tratamento da caquexia
US9545441B2 (en) 2012-09-18 2017-01-17 Xbiotech, Inc. Treatment of diabetes
CN105175504A (zh) * 2015-09-08 2015-12-23 苏州普罗达生物科技有限公司 血管性血友病因子抑制多肽及其应用
CN105175503A (zh) * 2015-09-08 2015-12-23 苏州普罗达生物科技有限公司 因子viii抑制多肽及其应用
JP7145162B2 (ja) 2017-02-16 2022-09-30 ヤンセン バイオテク，インコーポレイテッド 化膿性汗腺炎の処置
US10975146B2 (en) 2018-06-29 2021-04-13 Cedars-Sinai Medical Center Interleukin-1 inhibition for combination treatment of pancreatic cancer
CA3095675A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin 1 alpha (il-1a)
CA3095740A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin alpha (il-1a)
CA3095679A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleuken 1 alpha (il-1a)
CA3095676A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin 1 alpha (il-1a)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004100987A2 (en) * 2003-05-06 2004-11-25 Regeneron Pharmaceuticals, Inc. Methods of using il-1 antagonists to treat neointimal hyperplasia
JP2009503529A (ja) * 2005-08-02 2009-01-29 エクスバイオテク インコーポレーティッド ＩＬ−１α自己抗体を用いた血管障害の診断、処置、および予防
JP2009510025A (ja) * 2005-09-28 2009-03-12 サイトス バイオテクノロジー アーゲー インターロイキン−１コンジュゲート及びその使用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9802402D0 (sv) * 1998-07-03 1998-07-03 Karolinska Innovations Ab Method of diagnosing cardiovascular disease and early atherosclerosis
US6555579B2 (en) * 1998-08-13 2003-04-29 The Wistar Institute Methods for reducing atherosclerotic plaques
US20030040617A9 (en) * 1999-03-12 2003-02-27 Rosen Craig A. Nucleic acids, proteins and antibodies
US20030232054A1 (en) * 2000-01-25 2003-12-18 Tang Y. Tom Novel nucleic acids and polypeptides
US20030026806A1 (en) * 2000-10-27 2003-02-06 Amgen Inc. Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof
HN2004000285A (es) * 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
HUE029003T2 (en) * 2008-05-30 2017-01-30 Xbiotech Inc IL-1 alpha antibodies
JP5976319B2 (ja) * 2008-09-12 2016-08-23 エックスバイオテク, インコーポレイテッドXbiotech, Inc. 病原性単球の標的化

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004100987A2 (en) * 2003-05-06 2004-11-25 Regeneron Pharmaceuticals, Inc. Methods of using il-1 antagonists to treat neointimal hyperplasia
JP2009503529A (ja) * 2005-08-02 2009-01-29 エクスバイオテク インコーポレーティッド ＩＬ−１α自己抗体を用いた血管障害の診断、処置、および予防
JP2009510025A (ja) * 2005-09-28 2009-03-12 サイトス バイオテクノロジー アーゲー インターロイキン−１コンジュゲート及びその使用

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JPN5008011508; Ｄａｒｄｉｋ　Ａ，　ｅｔ　ａｌ．: 'Ｓｈｅａｒ　ｓｔｒｅｓｓ-ｓｔｉｍｕｌａｔｅｄ　ｅｎｄｏｔｈｅｌｉａｌ　ｃｅｌｌｓ　ｉｎｄｕｃｅ　ｓｍｏｏｔｈ　ｍｕｓｃｌｅ　ｃｅｌｌ　ｃｈｅｍｏｔａｘｉｓ　ｖｉａ　ｐｌａｔｅｌｅｔ-ｄｅｒｉｖｅｄ' Ｊｏｕｒｎａｌ　ｏｆ　Ｖａｓｃｕｌａｒ　Ｓｕｒｇｅｒｙ Ｖｏｌ．　４１，　Ｎｏ．　２, 200502, ｐ．　３２１-３３１ *
JPN5008011515; Ｇａｒｒｏｎｅ　Ｐ，　ｅｔ　ａｌ．: 'Ｇｅｎｅｒａｔｉｏｎ　ａｎｄ　ｃｈａｒａｃｔｅｒｉｚａｔｉｏｎ　ｏｆ　ａ　ｈｕｍａｎ　ｍｏｎｏｃｌｏｎａｌ　ａｕｔｏａｎｔｉｂｏｄｙ　ｔｈａｔ　ａｃｔｓ　ａｓ　ａ　ｈｉｇｈ　ａｆｆｉｎｉｔｙ　ｉｎｔｅ' Ｍｏｌｅｃｕｌａｒ　Ｉｍｍｕｎｏｌｏｇｙ Ｖｏｌ．　３３，　Ｎｏ．　７-８, 199605, ｐ．　６４９-６５８ *
JPN6012002566; Ｊｏｕｒｎａｌ　ｏｆ　Ｉｍｍｕｎｏｌｏｇｉｃａｌ　Ｍｅｔｈｏｄｓ Ｖｏｌ．２３６，Ｎｏ．１-２, 2000, ｐ１-８ *
JPN6012028876; Ｃａｒｄｉｏｖａｓｃｕｌａｒ　Ｒｅｓｅａｒｃｈ Ｖｏｌ．６６, 2005, ｐ．５８３-５９３ *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015019617A (ja) * 2013-07-19 2015-02-02 国立大学法人三重大学 閉塞性動脈硬化症モデル動物、るい痩研究用モデル動物、及び全身性アミロイドーシスモデル動物としての非ヒト哺乳動物

Also Published As

Publication number Publication date
EP2021033A2 (en) 2009-02-11
CN101448528A (zh) 2009-06-03
ATE551365T1 (de) 2012-04-15
US20090191149A1 (en) 2009-07-30
EP2021033A4 (en) 2010-02-24
WO2007132338A3 (en) 2008-06-12
WO2007132338A2 (en) 2007-11-22
EP2021033B1 (en) 2012-03-28
AU2007251239A1 (en) 2007-11-22
AU2007251239B2 (en) 2013-08-22
ES2384278T3 (es) 2012-07-03
CA2652274A1 (en) 2007-11-22

Similar Documents

Publication Publication Date Title
AU2007251239B2 (en) IL-1alpha immunization induces autoantibodies protective against atherosclerosis
US20110008282A1 (en) IL-1alpha immunization induces autoantibodies protective against atherosclerosis
Movsesyan et al. Reducing AD-like pathology in 3xTg-AD mouse model by DNA epitope vaccine—a novel immunotherapeutic strategy
Klinman et al. DNA vaccines: safety and efficacy issues
Regan et al. Characterization of cytokines associated with Th17 cells in the eyes of horses with recurrent uveitis
Bates et al. Mucosal adjuvant activity of flagellin in aged mice
US20150313977A1 (en) Immunogenic fragments of t-cell receptor constant domains and peptides derived therefrom
JP6955324B2 (ja) 医薬化合物を評価するための新規動物モデル
CN102256620B (zh) 用于治疗阿尔茨海默氏病的免疫治疗组合物
Thelemann et al. Absence of nonhematopoietic MHC class II expression protects mice from experimental autoimmune myocarditis
US20140227304A1 (en) Vaccines for preventing and treating alzheimer's disease
Irony-Tur-Sinai et al. Amelioration of autoimmune neuroinflammation by recombinant human alpha-fetoprotein
Austin et al. Short-term β-amyloid vaccinations do not improve cognitive performance in cognitively impaired APP+ PS1 mice.
Constantinescu et al. Modulation of susceptibility and resistance to an autoimmune model of multiple sclerosis in prototypically susceptible and resistant strains by neutralization of interleukin-12 and interleukin-4, respectively
Wildbaum et al. Augmentation of natural immunity to a pro-inflammatory cytokine (TNF-alpha) by targeted DNA vaccine confers long-lasting resistance to experimental autoimmune encephalomyelitis
Babai et al. Depletion of peritoneal CD5+ B cells has no effect on the course of Leishmania major infection in susceptible and resistant mice
JPS6121A (ja) ワクチンおよびその製造法
JP2010510986A (ja) Ｔｈ２媒介炎症症状治療のためのｔｓｌｐワクチン
Kim et al. Protective effect of the DNA vaccine encoding the major house dust mite allergens on allergic inflammation in the murine model of house dust mite allergy
JP5068505B2 (ja) 乳アレルギーモデル動物
Alderuccio et al. Organ-specific autoimmunity in granulocyte macrophage-colony stimulating factor (GM-CSF) deficient mice
Bungiro Jr et al. Interleukin-12 as an adjuvant for an antischistosome vaccine consisting of adult worm antigens: protection of rats from cercarial challenge
Bakela et al. Rescue of autoimmune hepatitis by soluble MHC class II molecules in an altered concanavalin A‐induced experimental model
JP7411970B2 (ja) 乳汁中のＩｇＡ抗体含有量の増加剤
JP2010509321A (ja) 種々の炎症状態の治療用の新規な組成物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100513

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100513

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110413

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120606

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120905

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130508

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130806

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130813

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140108